Topics
When a reader summarizes an article, the summary notes what new information the article adds to each relevant topic. Topics are broad categories or specific subtopics within them. Click a row for its description; click a category to expand its subtopics.
Alpha-synuclein seeding amplification assays, neurofilament light, DAT-SPECT imaging, smell testing and other diagnostic tools.
Dopamine-transporter imaging for diagnosis and progression tracking.
Plasma alpha-synuclein, neurofilament light and other circulating markers under evaluation.
Smartphones, wearables and passive sensing measuring tremor, gait and bradykinesia at home.
CSF, skin and other alpha-synuclein seed-amplification assays as diagnostic and trial-enrichment tools.
123I-MIBG cardiac sympathetic imaging — Lewy-spectrum specificity vs MSA and other parkinsonisms.
Skin-biopsy phosphorylated alpha-synuclein (Syn-One Test) for in-vivo synuclein pathology detection.
Caregiver burden, support groups, palliative care, advance directives, family resources.
Caregiver strain, depression, respite care and interventions targeting carer wellbeing.
Disability benefits, long-term-care insurance, advance directives and powers of attorney for PD families.
Grab bars, swivel cushions, smart-home setups and adaptive equipment for safety and independence.
Specialist palliative-care models for PD, including advance-care planning and end-of-life support.
Respite care, adult day programmes and structured social activities that relieve caregiving load.
Trial design, recruitment, interim and final results, regulatory updates.
Biomarker-enriched trials, prodromal cohorts and patient-recruitment networks.
Phase II/III results, regulatory decisions and discontinuations in PD therapeutics.
PPMI, Fox Insight, Luxembourg Parkinson Study and other longitudinal cohorts feeding biomarker and trial science.
FDA / EMA decisions, breakthrough designations and post-marketing safety actions in PD.
Mild cognitive impairment, Parkinson's disease dementia, depression, anxiety, apathy, hallucinations and impulse-control disorders.
PD-MCI and PD dementia — risk factors, screening, cholinesterase inhibitors and disease-modifying attempts.
PD depression — prevalence, screening, antidepressants and non-pharmacological treatments.
Visual hallucinations, illusions and PD psychosis — pimavanserin and antipsychotic safety.
Generalised, social and "off"-related anxiety, plus mechanistic and treatment evidence.
Motivational withdrawal distinct from depression; dopaminergic and behavioural strategies.
Pathological gambling, hypersexuality, compulsive eating and shopping linked to dopamine agonists.
Whole-diet patterns and eating strategies (Mediterranean / MIND, ketogenic, intermittent fasting, protein timing with levodopa, whole-foods plant-based). Specific foods and individual nutrients each have their own top-level category.
Time-restricted eating, alternate-day fasting and caloric restriction — autophagy signals and human evidence in PD.
Ketogenic and modified low-carb / high-fat diets and reported effects on motor and cognitive symptoms.
Whole-diet patterns rich in vegetables, fish, olive oil and whole grains and their association with PD risk and progression.
How dietary protein and large neutral amino acids interfere with levodopa absorption, and meal-redistribution strategies (protein-redistribution diet).
Vegetarian, vegan and whole-foods plant-based diets and their association with PD risk, progression and symptom control.
Alpha-synuclein aggregation, mitochondrial dysfunction, lysosomal dysfunction, gut-brain axis, neuroinflammation, oxidative stress, iron / ferroptosis, calcium dysregulation and the other biological pathways linked to Parkinson's.
Microglial activation, peripheral immune signals and inflammation-targeted therapies.
Dopamine quinones, DOPAL toxicity and aldehyde dehydrogenase deficits driving selective nigral vulnerability.
Reactive oxygen species, glutathione depletion and antioxidant defence in the substantia nigra.
Alpha-synuclein aggregation, oligomer toxicity, prion-like spread, and the body-first vs brain-first hypothesis.
Vagal-nerve spread, gut-microbiome changes and enteric alpha-synuclein pathology.
Iron accumulation in nigral neurons, lipid peroxidation and ferroptotic cell death — the rationale for iron chelation.
GBA/GCase, chaperone-mediated autophagy, macroautophagy and protein-clearance failure.
Complex I deficits, PINK1/Parkin mitophagy and bioenergetic failure in dopaminergic neurons.
Synaptic vesicle cycling, VPS35-linked endosomal trafficking and SV2C / VMAT2 dysfunction at the synapse.
BBB integrity, transporter dysfunction and the impact on drug delivery and neuroinflammation.
Cav1.3 L-type calcium channels, calcium-driven mitochondrial stress and the isradipine hypothesis.
NMDA-mediated excitotoxicity in basal-ganglia circuits and the rationale for amantadine and related compounds.
Parkin E3 ligase activity, proteasome impairment and protein-clearance failure outside the lysosomal route.
Gene therapy, stem-cell transplantation, alpha-synuclein immunotherapy (prasinezumab, cinpanemab), LRRK2/GBA-targeted therapy, GLP-1 agonists and other investigational treatments.
Small-molecule and antisense LRRK2-pathway inhibitors (e.g. BIIB122 / DNL151) under clinical evaluation.
iPSC- and ESC-derived dopaminergic cell-transplantation programmes and early-phase trials.
AAV-delivered gene therapies (AADC, GDNF, neurturin, GBA1) and other gene-modifying approaches.
Deferiprone and other iron chelators tested for slowing nigral degeneration (FAIRPARK-II and successors).
Active and passive immunotherapies (prasinezumab, cinpanemab, UB-312) targeting pathological alpha-synuclein.
Nilotinib-style and PD-purposed c-Abl tyrosine-kinase inhibitors (vodobatinib, IkT-148009 / risvodetinib).
Isradipine and other L-type calcium-channel blockers — Cav1.3 hypothesis and STEADY-PD3.
Faecal microbiota transplantation (FMT) and engineered microbial consortia for constipation and motor symptoms.
GCase activators and substrate-reduction therapies aimed at GBA-mutation carriers (ambroxol, venglustat, etc.).
Repurposing GLP-1 receptor agonists (exenatide, lixisenatide, semaglutide) as potential disease-modifying treatments.
Aerobic exercise, resistance training, boxing (Rock Steady), tai chi, dance, cycling, and other movement-based interventions.
High- and moderate-intensity cardio (running, brisk walking, cycling, treadmill, swimming) studied for neuroprotection, motor scores and cardiovascular fitness.
Slow martial-art practices studied for balance, falls reduction and quality of life.
Water-based exercise and hydrotherapy targeting balance, gait and pain in PD.
Stationary, outdoor and forced-rate (tandem) cycling and reported motor-symptom benefits.
Tango, ballet and other dance-based interventions targeting gait, balance, mood and social engagement.
HIIT and sprint-interval protocols and their effects on motor scores, fitness and putative neuroprotection.
Non-contact boxing programmes (Rock Steady Boxing and similar) and their effects on balance, gait and quality of life.
Progressive strength training with weights, machines or bands — targeting muscle mass, bradykinesia and falls prevention.
Treadmill, overground and Nordic / pole walking studied for gait, endurance and quality of life.
Yoga protocols (hatha, chair-based, adapted) studied for flexibility, balance, mood and quality of life.
Specific whole foods and food groups studied in relation to PD risk, symptoms or interaction with medication. Single compounds (caffeine, polyphenols, omega-3) live under nutriments; dietary patterns live under diet-and-nutrition.
Beer, wine and spirits — observational associations with PD risk and interactions with PD medications.
Berries (blueberries, strawberries, etc.) as a flavonoid-rich food group studied in PD risk cohorts.
Coffee consumption (caffeinated and decaf) as a food — the compound itself sits under nutriments/caffeine.
Milk, yoghurt and cheese consumption — observational links to PD incidence and the urate-lowering hypothesis.
Yoghurt, kefir, kimchi, sauerkraut and other fermented foods — gut-microbiome and constipation outcomes.
Oily fish and seafood as food (the omega-3 compound itself sits under nutriments/omega-3-fatty-acids).
Spinach, kale and other vegetables as components of neuroprotective dietary patterns.
Beans, lentils and especially fava beans / Mucuna pruriens — natural-levodopa interest and protein effects.
Tree nuts, peanuts and seeds — fat and polyphenol sources studied in cohort data.
Red and processed meat consumption — observational links to PD risk and inflammation.
Green and black tea consumption and reported associations with PD risk and progression.
Ultra-processed (NOVA-4) foods and beverages — observational links to PD risk and faster progression.
Oats, brown rice and other whole grains as components of MIND / Mediterranean diets.
Genes implicated in Parkinson's risk and progression: LRRK2, GBA1, SNCA, PARK7, PRKN, PINK1 and others.
LRRK2-G2019S and related variants — biology, prevalence and trial enrichment.
GBA1 (glucocerebrosidase) variants, their progression effect and GBA-targeted therapies.
GWAS loci, polygenic risk scores and idiopathic PD heritability estimates.
Autosomal-recessive young-onset PD genes and their mitochondrial mechanisms.
Alpha-synuclein gene multiplications and missense variants in familial PD.
VPS35, DJ-1 (PARK7), ATP13A2, DNAJC6, CHCHD2 and other rarer monogenic forms of PD.
Sleep hygiene, mindfulness, music, social engagement and other day-to-day practices.
Loneliness, social activity and their links to PD progression and mood.
Time outdoors, green-space exposure and gardening — mood, sleep and vitamin-D status (the compound itself sits under nutriments).
MBSR, meditation programmes and stress-reduction practices and their effects on PD symptoms.
Music-based therapy, choirs and singing groups — gait, voice and quality-of-life outcomes.
Behavioural sleep-improvement strategies — timing, environment, evening dopaminergic dosing, screen exposure.
Levodopa/carbidopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, amantadine, anticholinergics, istradefylline and symptom-management drugs.
Standard and extended-release levodopa-carbidopa, intestinal gel, inhaled and sublingual formulations — dosing strategies and off-time control.
Pramipexole, ropinirole, rotigotine and apomorphine — efficacy, dyskinesia risk and impulse-control side effects.
Immediate- and extended-release amantadine (Gocovri / Osmolex) for dyskinesia and off-time.
Trihexyphenidyl and benztropine — historical role for tremor, modern restraint over cognitive side effects.
Entacapone, opicapone and tolcapone — extending levodopa effect, off-time reduction and hepatic-safety considerations.
Selective A2A antagonist used as adjunctive therapy for off-time.
Selegiline, rasagiline and safinamide — symptomatic effect, off-time reduction and any disease-modification signal.
Mucuna pruriens seed extract used as a natural levodopa source — dosing variability, drug-interaction considerations and clinical evidence.
Selective 5-HT2A inverse agonist for PD psychosis — efficacy, mortality-warning history and ongoing trials.
On-demand subcutaneous apomorphine, sublingual apomorphine and inhaled levodopa (Inbrija) for sudden off episodes.
Tremor, bradykinesia, rigidity, postural instability, gait freezing, dyskinesia and on/off fluctuations.
Levodopa-induced dyskinesias — mechanisms, prevention and treatment (amantadine, DBS, etc.).
Wearing-off, motor fluctuations and strategies (formulation changes, rescue therapies) to smooth them.
Freezing of gait, festination and gait disorders; cueing and rehabilitation strategies.
Resting and action tremor — characterisation, measurement and treatment-specific responses.
Slowness of movement and muscle rigidity — measurement and treatment response.
Balance loss, retropulsion and falls — risk prediction and prevention strategies.
Hypophonia, dysarthria and prosodic changes — measurement and treatment response.
Autonomic dysfunction (constipation, orthostatic hypotension), pain, fatigue, hyposmia and other non-movement symptoms.
Musculoskeletal, dystonic, central and neuropathic pain in PD and their management.
Constipation in PD — gut-brain links, fibre, prokinetics, and prebiotic / probiotic trials.
Postural blood-pressure drops, droxidopa, midodrine and non-pharmacological strategies.
PD-related fatigue and the few interventions (exercise, stimulants, sleep optimisation) with any evidence behind them.
Erectile dysfunction, libido changes and hypersexuality in PD (the last partly medication-driven).
Excess saliva and drooling in PD — botulinum toxin injections, glycopyrrolate and behavioural strategies.
Olfactory dysfunction as prodromal marker and clinical symptom; smell-training evidence.
Overactive bladder, nocturia and urinary urgency in PD and their management.
Unintentional weight loss, sarcopenia and appetite changes in PD — nutritional management.
Individual nutrients, vitamins and bioactive compounds — typically measurable in blood, sold as supplements, or named as the active fraction of a food. Use these to relate specific compounds to disease pathways; whole foods sit under foods.
Caffeine the compound — A2A-receptor antagonism, motor symptoms, dyskinesia risk and neuroprotection signals.
Soluble and insoluble fibre — constipation, SCFA production and microbiome composition.
Iron accumulation in the substantia nigra, MRI iron mapping and iron-chelator trials (deferiprone).
Alpha-lipoic acid (ALA) — mitochondrial antioxidant and small combination trials.
Mitochondrial cofactor CoQ10 (ubiquinol) — historic neuroprotection trials and current rationale.
Creatine monohydrate — mitochondrial bioenergetic support and the negative NET-PD LS-1 trial.
Curcumin (turmeric extract) — anti-aggregation and anti-inflammatory rationale; absorption challenges.
Reduced glutathione (oral, intranasal, IV) and its role in nigral oxidative defence.
Melatonin supplementation — RBD, insomnia and antioxidant signals.
NAC as a glutathione precursor — antioxidant rationale and small clinical signals.
Niacin, nicotinamide riboside and NR / NMN — NAD+ boosting and small PD trials.
EPA, DHA and ALA — fish-oil and algae-oil supplementation and reported effects on mood, inflammation and progression.
EGCG, anthocyanins, quercetin and other polyphenols / flavonoids — antioxidant and anti-aggregation effects.
Live bacterial strains, prebiotic fibres and SCFA postbiotics — constipation and gut-brain trials.
Resveratrol (grape/wine polyphenol) — SIRT1 / autophagy signals and clinical evidence.
Urate as antioxidant, observational neuroprotection signal and the inosine SURE-PD3 trial.
B12 and folate status — levodopa-induced hyperhomocysteinaemia, neuropathy risk and cognition.
Vitamin D status and supplementation — motor scores, falls, bone health and immune signals.
Physical, occupational and speech therapy — including LSVT BIG/LOUD, swallowing therapy and balance training.
Balance training, perturbation-based programmes and falls-risk reduction.
Visual lines, laser cues, metronomes and rhythmic auditory cueing for gait freezing.
Lee Silverman Voice Treatment protocols for amplified movement and voice training.
OT-led interventions: handwriting, dressing, fine-motor tasks and home-task adaptation.
Parkinson Wellness Recovery functional-movement programme — large-amplitude exercises adaptable across stages.
Dysarthria, dysphagia, expiratory-muscle strength training and aspiration prevention.
Remote-delivered physiotherapy and speech therapy — video platforms and apps for home programmes.
REM sleep behaviour disorder (RBD), insomnia, daytime sleepiness and sleep-related interventions.
RBD as a prodromal marker, surveillance cohorts and management (melatonin, clonazepam).
Sleep-onset and sleep-maintenance problems in PD, plus night-time motor and urinary contributors.
Excessive daytime sleepiness, sleep attacks and contribution from dopaminergic medication.
Deep-brain stimulation (DBS), focused ultrasound, levodopa-carbidopa intestinal gel (LCIG) pumps and other procedural interventions.
Sensing-enabled DBS systems that adjust stimulation in real time based on neural biomarkers.
STN/GPi DBS implantation, patient selection and long-term outcomes on motor symptoms and quality of life.
MR-guided focused ultrasound thalamotomy / pallidotomy / subthalamotomy for tremor and dyskinesia.
Continuous intestinal levodopa-carbidopa gel (LCIG / Duopa), foslevodopa subcutaneous infusion (Vyalev / Produodopa) and apomorphine pumps for advanced fluctuations.